SAN DIEGO, CAAugust 20, 2014Inc. magazine today ranked global genetic testing company Pathway Genomics No. 173, with a three-year growth rate of 2,415.5%, on its 33rd annual Inc. 500|5000, an exclusive ranking of the nation’s fastest-growing private companies. The list represents the most comprehensive look at the most important segment of the economy — America’s independent entrepreneurs. Companies such as Yelp, Pandora, Timberland, Dell, Domino’s Pizza, LinkedIn, Zillow, and many other well-known names gained early exposure as members of the Inc. 500|5000.

“A heartfelt congratulations to each company that made the Inc. 500|5000. We are honored to be included among the top-tier of innovative companies in the nation,” said Jim Plante, Pathway Genomics’ founder and CEO. “Since the day Pathway was founded, it has been our goal to provide the most accurate and pioneering services possible to physicians and their patients. These last few years have been an incredible ride in developing a suite of powerful tests that can benefit patients worldwide to truly make an impact on global health – and we’re just getting started.”

As a government-accredited clinical laboratory and forward-thinking healthcare company, Pathway Genomics has numerous actionable genetic tests that can identify a person’s genetic risk for cancer, cardiac conditions, inherited diseases, nutrition and exercise response, and drug response for medications, specifically those used in pain management and mental health.

Over the last two months, Pathway Genomics has launched a leading-edge next-generation sequencing breast cancer risk genetic test, called BRCATrueTM, and co-hosted a fundraiser benefiting Susan G. Komen that raised more than $300,000 for the organization. The company also unveiled the BRCA One for OneTM program – for every qualified BRCATrue test ordered, one test is donated to a person in need, up to $10 million of free testing. It is the only program of its kind in the history of the medical community. Pathway Genomics also has a financial assistance program for patients who cannot afford testing.

The 2014 Inc. 500, unveiled in the September issue of Inc. (available on newsstands August 20 to November 15 and on Inc.com), is the most competitive crop in the list’s history. To make the cut, companies had to have achieved a staggering minimum of 942.6% in sales growth. The Inc. 500’ s aggregate revenue is $15.2 billion, with a median three-year growth of 1,828%, generating 23,000 jobs over the past three years. Complete results of the Inc. 500|5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/inc5000.

“What surprises me, even though I know it’s coming, is the sheer variety of the paths our entrepreneurs take to success, thematically reflecting how our economy has evolved,” said Inc. President and Editor-In-Chief Eric Schurenberg. “This year there are far more social media and far fewer computer hardware businesses than there were, say, six years ago. But what doesn’t change is the fearsome creativity unleashed by American entrepreneurship.”

The annual Inc. 5000 event honoring all the companies on the list will be held from October 15 through 17, 2014 in Phoenix. Speakers include some of the greatest entrepreneurs of this and past generations, such as Michael Dell, Martha Stewart, host of the CNBC show “The Profit” Marcus Lemonis, Container Store Founder and CEO Kip Tindell, and Chobani Founder and CEO Hamdi Ulukaya.

More About Inc. and the Inc. 500|5000

Methodology
The 2014 Inc. 500|5000 is ranked according to percentage revenue growth when comparing 2010 to 2013. To qualify, companies must have been founded and generating revenue by March 31, 2010. They had to be U.S.-based, privately held, for profit, and independent–not subsidiaries or divisions of other companies–as of December 31, 2013. (Since then, a number of companies on the list have gone public or been acquired.) The minimum revenue required for 2010 is $100,000; the minimum for 2013 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Companies on the Inc. 500 are featured in Inc.’s September issue. They represent the top tier of the Inc. 5000, which can be found at http://www.inc.com/inc5000.

About Inc. and the Inc. 500|5000
Founded in 1979 and acquired in 2005 by Mansueto VenturesInc. is the only major brand dedicated exclusively to owners and managers of growing private companies, with the aim to deliver real solutions for today’s innovative company builders.  Total monthly audience reach for the brand has grown significantly from 2,000,000 in 2010 to over 6,000,000 today.  For more information, visit http://www.inc.com/.

The Inc. 500|5000 is a list of the fastest-growing private companies in the nation. Started in 1982, this prestigious list of the nation’s most successful private companies has become the hallmark of entrepreneurial success. The Inc. 500|5000 Conference & Awards Ceremony is an annual event that celebrates their remarkable achievements. The event also offers informative workshops, celebrated keynote speakers, and evening functions. For more information on Inc. and the Inc. 500|5000 Conference, visit http://www.inc.com/.

SAN DIEGO, CAAugust 5, 2014Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced its laboratory director, Dr. Linda Wasserman, was an honorary speaker at the second annual National Women’s Survivors Convention. Held last week in Nashville, Tennessee, the convention serves as a place for women survivors of cancer to come together over issues surrounding survivorship. The purpose of the convention is to help women re-enter their lives by supporting, educating, and connecting them with other women whose lives have been touched by cancer. This year’s convention hosted more than 800 people affected by cancer.

Titled “Genetic Testing: How Can It Help My Family and Me?,” Dr. Wasserman’s talk focused on indications for genetic testing for cancer risk and what is involved. She discussed the benefits and risks, as well as how cancer patients and their families can use the information.

“I was delighted to have the opportunity to present and share my experience with people at this convention. Genetic testing is a vital component in assessing cancer risk, and we are at a time in medical care where this information is becoming more and more accessible.” said Dr. Wasserman. “Our ultimate goal as a clinical laboratory is to ensure all people who need BRCA testing get it, regardless of how much money they have.”

Dr. Wasserman is the former medical and laboratory director of the Molecular Genetics Laboratory at UC San Diego. She established and directed the DNA Sequencing and Molecular Pathology laboratories within the UCSD Moores Cancer Center.

Over the last two months, Pathway Genomics has launched a leading-edge next-generation sequencing BRCA1/2 test, called BRCATrueTM, and co-hosted a fundraiser benefiting Susan G. Komen that raised more than $300,000 for the organization. The company also unveiled its BRCA One for OneTM program – for every qualified BRCATrue test ordered, one test is donated to a person in need through participating health care providers, up to $10 million of free testing. It is the only program of its kind in the history of the medical community. Pathway Genomics also has a very competitive and patient-friendly financial assistance program for patients who cannot afford testing.

Embrey brings extensive executive health and medical experience in federal service as well as military and veteran affairs issues to the board

SAN DIEGO, CAJuly 10, 2014Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that Ellen Embrey, B.S., has joined its strategic advisory board. Embrey earned a bachelor’s degree from Virginia Tech and was twice awarded the Department of Defense (DOD) Distinguished Civilian Service Award. Embrey brings extensive executive health and medical experience in federal service as well as military and veteran affairs issues to the board.

Embrey acted as the Assistant Secretary of Defense for Health Affairs and the Director of TRICARE Management Activity during the presidential transition period in 2009-2010. She was also the Deputy Assistant Secretary of Defense for Force Health Protection and Readiness, leading significant changes in DOD policies and programs affecting deployment and combat casualty medicine, health promotion and preventive medicine, medical readiness and public health emergency preparedness and response.

“I am passionate about discovering the best possible health promotion, prevention and treatment services for America’s service members, veterans, and their families,” said Embrey. “Pathway’s cutting-edge testing provides an exquisite opportunity for care providers in both DOD and VA systems of care to understand and leverage patient-specific genetic information to design effective and personalized prevention and treatment programs for common health issues such as obesity, depression, pain management, and cancer.”

Embrey is currently CEO of Stratitia Inc., a firm providing medical logistics, scientific and technical subject matter experts, program and project management, management consulting, strategic planning, and health facility planning and design services in the healthcare, IT management, and emergency response preparedness sectors.

“We’re very fortunate to have someone as widely respected and accomplished as Ellen on our advisory board,” said Jim Plante, Pathway Genomics CEO. “Now that Pathway is a certified contractor to the federal government, having the benefit of Ellen’s guidance and experience are invaluable in helping to ensure the military and veteran community has widespread availability of these critical new healthcare tools.”

Event Marks One-Year Anniversary of US Supreme Court Decision to Ban Human Gene Patenting

Dr. Judith A. Salerno, president and CEO of Susan G. Komen, and Jim Plante, founder and CEO of Pathway Genomics

SAN DIEGO, CAJune 17, 2014  – Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, last week co-hosted a fundraiser benefiting Susan G. Komen. Jim Plante, founder and CEO of Pathway Genomics, and Ryan Kavanaugh, CEO of Relativity, were the hosts of the event, titled Pathway to the Cure. The fundraiser, held in Santa Monica, California, raised more than $300,000 through generous donations made by attendees of the event.

“We’re working with Susan G. Komen to help spread awareness about breast cancer, and to help as many women as we can in the battle against this disease,” said Plante. “We’re truly working to save lives, and ultimately prevent breast cancer forever.”

Attended by notable celebrities, such as Adrian Grenier and Sophia Bush, the event’s entertainment for the evening was provided by DJ Zen Freeman and DJ Nikki Pennie, and included a musical performance by world-renowned artist Kesha, whose hits include “Tik Tok,” and the wildly popular “Timber,” a collaboration with rapper Pitbull.

World-renowned artist Kesha performing at Pathway to the Cure.

“This was an extraordinary event. We are grateful for the commitment and generosity of supporters such as Relativity and Pathway Genomics that will help us save lives in California and around the world, ” said Susan G. Komen president and CEO, Judith A. Salerno, M.D., M.S.

The fundraiser comes at the one-year anniversary of the U.S. Supreme Court’s unanimous decision to ban the patenting of naturally occurring genes, such as BRCA, the gene linked to breast cancer.

“We firmly believe that genetic testing for the risk of breast cancer is every person’s right and should not be overpriced and monopolized by massive corporations,” said Plante. “Pathway’s BRCA test price and our BRCA One for One program is a testament to this dedication to serve those who cannot afford this potentially life-saving test.”

Earlier this month, Pathway Genomics launched its next-generation sequencing and deletion/duplication analysis, BRCATrueTM, which can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry. To enhance the accessibility of the test, the company also launched the first-of-its-kind BRCA One for OneTM program – for every qualified BRCATrue test ordered, one test is donated to a person in need through patient advocacy organizations, up to $10 million of free testing.

To learn more about BRCATrue, visit www.pathway.com/brcatrue. For more details about the BRCA One for One program, visit www.brcaoneforone.com.

Pathway Genomics today announced it will vigorously defend itself against a patent infringement suit filed on June 13, 2014, by Myriad Genetics, Inc. and other plaintiffs. Ironically, the lawsuit was filed on the one-year anniversary of the U.S. Supreme Court’s decision to strike down Myriad’s monopoly on genetic information related to a woman’s risk of breast cancer. Undeterred by the Supreme Court’s action, Myriad has continued to engage in conduct intending to suppress women’s options for breast cancer screening, including this latest action.

“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO.

Pathway Genomics recently began offering BRCATrue™, its genetic test to help individuals understand their genetic risk for developing breast, ovarian and other types of cancers. It also launched its BRCA One for One™ program under which Pathway Genomics will provide millions of dollars of free testing to uninsured women. Additionally, as another step in its fight against breast cancer, Pathway Genomics teamed up with Relativity Media last week to co-host a VIP fundraiser in Los Angeles benefiting Susan G. Komen in support of breast cancer testing and awareness.

“We are a company trying to do good in the world. Forty-eight hours after we raised hundreds of thousands of dollars for Susan G. Komen to fight breast cancer and announced our donation of $10 million of free genetic testing for women in need, Myriad Genetics slaps us with this unwarranted lawsuit,” said Jim Plante, Pathway Genomics’ founder and CEO. “Given their pattern of filing lawsuits against other companies broadening access to this life-saving technology in clear disregard of the Supreme Court’s decision last year, this lawsuit is not unexpected. We do not infringe on any valid patent claims and are prepared to vigorously defend ourselves.”

BRCATrue is a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry.

“We believe that no corporation should have a monopoly over an individual’s genes. Every person should have access to vital information about their own body,” said Plante.

To enhance the accessibility of this important genetic test, Pathway Genomics has developed the BRCA One for One program – for every qualified BRCATrue test ordered, one test is donated to a person in need through patient advocacy organizations, up to $10 million of free testing.

“We are on a mission to make genetic testing more accessible and affordable, especially testing related to cancer screening, one of the leading causes of death in the world. We believe that no corporation should have a monopoly over an individual’s genes. Every person should have access to vital information about their own body,” said Plante.

BRCATrue offers physicians an easy to interpret and clinically actionable report, advanced variant classification, as well as a rapid 2-week turnaround time. BRCATrue is the first step of many that will occur this year to demonstrate Pathway Genomics’ leadership in clinical genomics and commitment to having the most comprehensive cancer-testing menu. To learn more about BRCATrue, visit www.pathway.com/brcatrue. For more details about the BRCA One for One program, visit www.brcaoneforone.com.

Commitment to Sharing Genetic Information: Pathway Genomics Supports the Free the Data Movement

Today, Myriad and other labs hold their clinically-observed genetic variants in proprietary databases that are not freely accessible to the medical community. Pathway Genomics agrees with the Free the Data movement – these mutations should not be trade secrets. By broadening access and sharing genetic information, we can collectively harness the power of the genome to improve our understanding of disease and improve healthcare for everyone. Providing broad access to genetic testing will allow the medical community to collectively diagnose disease better, faster and cheaper; offer patients more effective healthcare and reduce costs to the healthcare system. Pathway Genomics supports the Free the Data movement and will make its BRCA1 and BRCA2 data available on ClinVar. For more information about the Free the Data movement, visit www.free-the-data.org.

Pathway Genomics today announced it has launched BRCATrueTM, a next-generation sequencing and deletion/duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of cancer. BRCATrue has a sensitivity of >99.99% and the broadest coverage across BRCA1/2 in the industry.

To enhance the accessibility of this important genetic test, Pathway Genomics has developed the BRCA One for OneTM program – for every qualified BRCATrue test ordered, one test is donated to a person in need through patient advocacy organizations, up to $10 million of free testing.

“Pathway’s mission is to ensure that people in need receive genetic testing regardless of their economic or insurance status,” said Jim Plante, Pathway Genomics’ founder and CEO. “Offering the industry’s best BRCA genetic test and making it accessible to a wide range of people is a vital objective in this mission.”

Recent studies show that up to 80 percent of families with multiple cases of breast and ovarian cancer have been attributed to BRCA1/2 mutations. Mutations in BRCA genes can occur in men and women across all ethnicities, and although anyone can have mutations in one of the BRCA genes, some groups are more likely to be affected such as those with a family history of cancer and people of Ashkenazi Jewish descent.

“One out of every eight women will be affected by breast cancer in her lifetime,” said Ardy Arianpour, Pathway Genomics’ chief strategy officer. “In the history of the medical community, no clinical laboratory has offered such an unprecedented program as BRCA One for One. By making our test more accessible, we aim to make a substantial impact in the prevention of breast cancer and help further raise awareness by partnering with global patient advocacy organizations.”

BRCATrue offers physicians an easy to interpret and clinically actionable report, advanced variant classification, as well as a rapid 2-week turnaround time. BRCATrue is the first step of many that will occur this year to demonstrate Pathway Genomics’ leadership in clinical genomics and commitment to having the most comprehensive cancer-testing menu. To learn more about BRCATrue, visit www.pathway.com/brcatrue. For more details about the BRCA One for One program, visit www.brcaoneforone.com.

New members include acclaimed genetic counselors Jill Davies, M.S., CCGC, director of genetics and genomics at Medcan Clinic, and Elissa Levin, M.S., CGC, assistant professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai

 

 MedMtSinai

 

Pathway Genomics has added industry-leading genetic counselors Jill Davies, M.S., CCGC, and Elissa Levin, M.S., CGC, to its genetic advisory board.

“Collaborating with expert genetic counselors is a critical part of Pathway’s dedication to providing clinical genetic information to patients and their physicians. Part of that dedication is to help patients learn about their genetic results through a genetic counselor.”

Linda Wasserman, M.D., Ph.D.
Laboratory Director, Pathway Genomics
Former Director of the Clinical Cancer
Genetics Care Unit, UC San Diego Moores Cancer Center

With more than 10 years as a genetic counselor, Jill Davies, M.S., CCGC, is the current director of genetics and genomics at Medcan Clinic, where she has developed a leading-edge genetics program with a range of services. Her special interest is in the role of genetics in primary care and preventive medicine, focusing on bringing the most advanced genetics knowledge to individuals to help them optimize health and manage risk for disease. As the co-investigator on the Personal Genome Project Canada (PGPC), in 2012 she became the first Canadian to have her whole genome sequenced as part of this project. Davies is an active member of the Ontario Personalized Medicine Network, the National Society of Genetic Counselors and is a Canadian board-certified genetic counselor.

Elissa Levin, M.S., CGC, is the head of Genomics and Integrative Health Innovations and assistant professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai. Previously she was at Life Technologies, where she developed and led the clinical support services department, providing clinical genomics expertise to the global organization. Levin began her career working in academic medical centers where she provided clinical genetic counseling for the Division of General and Metabolic Genetics at the University of California San Francisco and coordinated a multicenter, NIH-funded trial on the genetic basis of congenital heart disease at the Children’s Hospital of Philadelphia.

Pathway Genomics’ advisory board consists of leaders in various fields including genetic counseling, oncology, pharmacogenomics, endocrinology, bioinformatics, biostatistics, behavioral genetics, nutrigenomics, and human epigenetics. To view the company’s full advisory board, visit www.pathway.com.

Pathway Genomics today announced that Nature Genetics founding editor Kevin Davies, Ph.D., has joined its scientific advisory board.

“I believe Pathway is poised to make a major contribution to clinical diagnostics and improving the wellness of millions of patients. I hope to make a modest contribution to that effort.”

Kevin Davies, Ph.D.
Author of The $1,000 Genome and Cracking the Genome
Founding Editor, Nature Genetics

“I have followed Pathway closely for many years, reporting on the launch of the company in my book, The $1,000 Genome,” said Davies. “I believe Pathway is poised to make a major contribution to clinical diagnostics and improving the wellness of millions of patients. I hope to make a modest contribution to that effort.”

A highly respected science journalist, editor, and publisher with more than 20 years of experience at the forefront of advances in genetics and medicine, Davies is currently a vice president with the American Chemical Society, the largest scientific society in the world, where he serves as publisher of Chemical & Engineering News, the society’s weekly magazine. He has also served as editor-in-chief for Cell Press and was the founding editor of Bio-IT World magazine.

“Kevin is a vital thought leader in the genomics space and his work is a significant contribution to progress in the field,”

Ardy Arianpour
Chief Strategy Officer
Pathway Genomics

“Kevin is a vital thought leader in the genomics space and his work is a significant contribution to progress in the field,” said Ardy Arianpour, Pathway Genomics’ chief strategy officer. “We are exceptionally pleased to collaborate with an opinion leader of his status.”

Born in London, Davies studied biochemistry and molecular genetics at the Universities of Oxford and London before moving to the United States. He conducted postdoctoral fellowships at MIT and Harvard Medical School before moving into science publishing. Davies is the author of three popular-science books on the medical and societal implications of the genomics revolution, including Cracking the Genome and most recently The $1,000 Genome. He is a sought-after public speaker and an occasional technical consultant to the film industry, most recently serving as genetics consultant for the film Decoding Annie Parker.

Pathway Genomics’ scientific advisory board consists of leaders in various fields including oncology, pharmacogenomics, endocrinology, bioinformatics, biostatistics, behavioral genetics, nutrigenomics, and human epigenetics. To view the company’s full scientific advisory board, visit www.pathway.com.

Pathway Genomics has added Illumina NextSeq 500 systems to its force of NGS sequencers, enhancing the company’s established and highly efficient laboratory processes.

 

The NextSeq 500’s push-button operation provides a one-day turnaround time for an array of popular sequencing applications such as a single human genome, and up to 16 exomes, 20 transcriptomes, 48 gene expression samples, 20 non-invasive prenatal samples, and 96 targeted panels. Additionally, with the sequencer’s streamlined informatics, sequencing data can be run through a range of commercial pipelines.

The NextSeq 500 provides a one-day turnaround time for an array of popular sequencing applications.

Continue reading »

Pathway Genomics announced that world-renowned geneticist George Church, Ph.D., has joined its scientific advisory board. He is the founder of the Personal Genome Project, a professor of genetics at Harvard Medical School, and director of the Harvard NHGRI Center of Excellence in Genomic Science.

Dr. Church is the founder of the Personal Genome Project, a professor of genetics at Harvard Medical School, and director of the Harvard NHGRI Center of Excellence in Genomic Science.

Continue reading »